Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (25 June 2018)

Below are what we consider to have been the most notable PCT patent applications relevant to the Life Sciences sector in Australia that have been published since 13 June 1998. For PCT patent applications prior to that date click here.

• ​WO/2016/061619: A method of treatment, Hexima, 28 April 2016
• WO/2016/061615: Methods of reducing mammographic breast density and/or breast cancer risk, Chavah, 28 April 2016
• WO/2016/058056: Novel imaging composition and uses thereof, University of Melbourne, 21 April 2016
• WO/2016/054671: Selenosugars and therapeutic uses thereof, Carl Schiesser, Corin Storkey and Michael Davies, 14 April 2016
• WO/2016/049677: Method of treating cancer, Walter and Eliza Hall Institute of Medical Research, 7 April 2016
• WO/2016/033660: Antiviral agents and uses thereof, Griffith University, 10 March 2016
• WO/2015/196250: Lipid comprising docosapentaenoic acid, Commonwealth Scientific and Industrial Research Organisation, Grains Research and Development Corporation and Nuseed Pty Ltd, 30 December 2015
• WO/2015/191595: A novel formulation of meloxicam, iCeutica Pty Ltd, 17 December 2015
• WO/2015/184509: Methods of treating neurodevelopmental diseases and disorders, Deakin University and Florey Institute of Neuroscience and Mental Health, 10 December 2015
• WO/2015/181641: Combination of lenalidomide or pomalidomide and CD38 antibody-attenuated interferon-alpha constructs, and the use thereof, Teva Pharmaceuticals Australia, 3 December 2015
• WO/2015/159103: Piperazine derivatives for treating disorders, University of Nottingham and Newsouth Innovations, 22 October 2015
• WO/2015/149105: Method for treating Chronic Lymphocytic Leukemia, Bionomics Ltd, 8 October 2015
• WO/2015/135024: Adjuvant therapy to standard of care (SOC) diuretic treatment, Madeleine Pharmaceuticals Pty Ltd, 17 September 2015
• WO/2015/117199: Anti-metalloprotease antibody for diagnosis and treatment of cancers, Monash University, Memorial Sloan-Kettering Cancer Centre and Ludwig Institute for Cancer Research, 13 August 2015
• WO/2015/109362: Method for reducing total gas production and/or methane production in a ruminant animal, Commonwealth Scientific and Industrial Research Organisation, Meat and Livestock Australia Ltd and James Cook University, 30 July 2015
• WO/2015/089587: Lipid comprising long chain polyunsaturated fatty acids, Commonwealth Scientific and Industrial Research Organisation, Nuseed Pty Ltd and Grains Research and Development Corporation, 25 June 2015
• WO/2015/077845: Method of treating nephropathy, CSL Ltd, 4 June 2015
• WO/2015/074115: Prevention and treatment of toxicosis, Meat and Livestock Australia and Charles Sturt University, 28 May 2015
• WO/2015/073803: Neurodegenerative disorders and methods of treatment and diagnosis thereof, University of Queensland, 21 May 2015
• WO/2015/061839: Cell culture method, Isopogen Pty Ltd, 7 May 2015
• WO/2015/061832: Pharmaceutical combinations for the treatment of cancer, PharmAust Ltd and University of New South Wales, 7 May 2015
• WO/2015/061826: Novel scorpion toxin analogue and method for treating autoimmune diseases, Monash University, 7 May 2015
• WO/2015/049589: Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma, EnGeneIC, 9 April 2015
• WO/2015/039173: Compositions for the treatment of hypertension and/or fibrosis, Vectus Biosystems, 26 March 2015
• WO/2015/037747: Anticancer agent comprising aminoacetonitrile compound as active ingredient, Nihon Nohyaku Co. (Japan) and PharmAust Ltd, 19 March 2015
• WO/2015/027296: A method of treatment, University of Melbourne, 5 March 2015
• WO/2015/013581: Combinatorial methods to improve the therapeutic benefit of bisantrene, Race Oncology, 29 January 2015
• WO/2015/013579: Compositions to improve the therapeutic benefit of bisantrene, Update Pharma, 29 January 2015
• WO/2015/006803: UV absorbing compounds, compositions comprising same and uses thereof, Coral Sunscreen Pty Ltd, 22 January 2015
• WO/2014/194362: Process for preparing Apolipoprotein A-I (APO A-I), CSL Ltd, 11 December 2014
• WO/2014/179831: Dosage projectile for remotely treating an animal, Smartvet, 13 November 2014
• WO/2014/179754: High osmolarity antimicrobial composition containing one or more organic solvents, Next Science, 6 November 2014
• WO/2014/178820: Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b, Teva Pharmaceuticals Australia Pty Ltd, 6 November 2014
• WO/2014/176634: Methods for treating bacterial infections, Neoculi, 6 November 2014
• WO/2014/176394: Vitamin D receptor/SMAD genomic circuit gates fibrotic response, Salk Institute for Biological Studies and University of Sydney, 30 October 2014
• WO/2014/173873: Complex, CSL Ltd, 30 October 2014
• WO/2014/140797: MicroRNA-based approach to treating malignant pleural mesothelioma, Asbestos Diseases Research Foundation, 18 September 2014
• WO/2014/138796: Dosage regimen for therapeutic method, Madeleine Pharmaceuticals, 18 September 2014
• WO/2014/134689: Polymer conjugate for delivery of a bioactive agent, Polyactiva, 12 September 2014
• WO/2014/124487: Ligand binding molecules and uses thereof, Vegenics, 21 August 2014
• WO/2014/121342: Methods of treating topical microbial infections, Luoda Pharma, 14 August 2014
• WO/2014/117220: Anti-CD83 antibodies and use thereof, Transbio with the University of Queensland and the University of California (US), 7 August 2014
• WO/2014/100852: Inhibition of cancer growth and metastasis, Royal Melbourne Institute of Technology and Abregen Pty Ltd, 3 July 2014
• WO/2014/094043: Methods of generating cells with multilineage potential, University of New South Wales, 26 June 2014
• WO/2014/078900: Anti-pathogenic methods, Hexima, 30 May 2014
• WO/2014/075125: Soluble mediator, Walter and Eliza Hall Institute of Medical Research, 22 May 2014
• WO/2014/071449: Neuroactive steroids and their use to facilitate neuroprotection, Goodchild Investments, 15 May 2014
• WO/2014/066951: Dental compositions, Ozdent, 8 May 2014
• WO/2014/066943: Reconstituted HDL formulation, CSL Ltd, 8 May 2014
• WO/2014/063198: A radioisotope concentrator, Cyclopharm, 1 May 2014
• WO/2014/059489: Improved human herpesvirus immunotherapy, Queensland Institute of Medical Research, 24 April 2014
• WO/2014/059484: Cancer therapy using miRNAs, University of Western Australia, 24 April 2014
• WO/2014/059429: Small molecules inhibiting oncoprotein Myc, Health Research (US), Panacela Labs (US), Children's Cancer Institute, 17 April 2014
• WO/2014/059034: NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation, Harvard University and University of New South Wales, 17 April 2014
• WO/2014/056025: Improved process for purifying lactoferrin from milk and products thereof, Murray Goulburn Co-Operative Co., 17 April 2014
• WO/2014/043743: Viscous haemostatic compostions and method of treatment, Eupharma, 27 March 2014
• WO/2014/041425: Daptomycin formulations and uses thereof, Hospira Australia, 20 March 2014
• WO/2014/036608: Methods and products for preventing and/or treating metastatic cancer, Adelaide Research & Innovation, 13 March 2014
• WO/2014/032082: Modified human rotaviruses and uses therefor, Murdoch Childrens Research Institute, 6 March 2014
• WO/2014/028968: Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof, Peter Maccallum Cancer Institute, 27 February 2014
• WO/2014/026243: VEGFR3 inhibitors, Cancer Therapeutics CRC, 20 February 2014
• WO/2014/026242: VRGFR3 inhibitors, Cancer Therapeutics CRC, 20 February 2014
• WO/2014/022879: Compounds for the treatment of mTOR pathway related diseases, Pitney Pharmaceuticals, 13 February 2014
• WO/2014/019025: EpCAM aptamer for detection of cancer stem cells, Deakin University, 6 February 2014
• WO/2014/008542: Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders, Brien Holden Vision Institute, 16 January 2014
• WO/2014/005194: Immunological reagents and uses therefor, University of Melbourne, Monash University and University Of Queensland, 9 January 2014
• WO/2014/000033: Polymer-NSAID conjugate, Polyactiva, 3 January 2014
• WO/2013/192566: Itraconazole compositions and dosage forms, and methods of using the same, Mayne Pharma, 27 December 2013
• WO/2013/185184: Production of long chain polyunsaturated fatty acids in plant cells, Commonwealth Scientific and Industrial Research Organisation, Grains Research and Development Corporation and Nuseed Pty Ltd, 19 December 2013WO/2013/185178, Nanoemulsions, University of Queensland, 19 December 2013
• WO/2013/181713: Release media, University of Queensland, 12 December 2013
• WO/2013/181694: Compositions and methods for treating Crohn's disease and related conditions and infections, Gaurav Agrawal, 12 December 2013
• WO/2013/177608: Method of treating Scedosporium spp. infection, Biodiem Ltd, 5 December 2013
• WO/2013/173874: Composition and method for management of diabetes or pre-diabetes, Omniblend Innovation, 28 November 2013
• WO/2013/173129: Treatment of AMD using AAV sFlt-1, Avalanche Australia Pty Ltd and Lions Eye Institute, 21 November 2013
• WO/2013/170317: Liquid formulation, Luoda Pharma Pty Ltd, 21 November 2013
• WO/2013/170315: A method of treatment and agents useful for same, Paranta Biosciences Ltd, 21 November 2013
• WO/2013/170305: Cellular vaccine and method of inducing an immune response in a subject, University of Adelaide, 21 November 2013
• WO/2013/166555: Methods of treating cancer using angiogenin or an angiogenin agonist, Murray Goulburn Co-Operative Co. Ltd, 14 November 2013
• WO/2013/166545: 6-oxopurine phosphoribosyltransferase inhibitors, University of Queensland and Institute of Organic Chemistry and Biochemistry, 14 November 2013
• WO/2013/152392: Viral polymerase inhibitors, Biota, 17 October 2013
• WO/2013/152391: Viral polymerase inhibitors, Biota, 17 October 2013
• WO/2013/150382: Herbal compositions for the prevention or treatment of Benign Prostatic Hyperplasia and related disorders, Tracey Seipel, 10 October 2013
• WO/2013/150292: Composition for the treatment of inflammatory and immune disorders, Eaglepharma, 10 October 2013
• WO/2013/138863: Kinase inhibitors for the treatment of cancer, NewSouth Innovations, 26 September 2013
• WO/2013/134822: Method for treating inflammation, James Cook University, 19 September 2013
• WO/2013/128283: Inhalable pharmaceutical compositions, iCeutica Pty Ltd, 6 September 2013
• WO/2013/124666: Tumour Necrosis Factor receptor fusion proteins and methods of using the same, Nexvet, 29 August 2013
• WO/2013/113774: Factor XII inhibitors for the treatment of neurological inflammatory disorders, CSL Ltd, Julius-Maximilians-Universitaet-Wuerzburg and Westfaelische Wilhelms-Universitaet Muenster , 8 August 2013
• WO/2013/113074: Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor, Antisense Therapeutics, 8 August 2013
• WO/2013/091004: Prevention and treatment of Mycobacterium infection, University of Sydney and Centenary Institute of Cancer Medicine and Cell Biology, 27 June 2013
• WO/2013/091001: A peptide-hydrogel composite, University of Sydney, 27 June 2013
• WO/2013/090989: Method of treating inflammatory bowel disease, CSL Ltd, 27 June 2013
• WO/2013/088250: Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors, EnGeneIC, 20 June 2013
• WO/2013/085904: Oral spray formulations and methods for administration of sildenafil, Suda Pharmaceuticals, 13 June 2013
• WO/2013/082656: Cage amine ligands for metallo-radiopharmaceuticals, University of Melbourne, 13 June 2013
• WO/2013/082655: Functionalisation of cage amine ligands for metallo-radiopharmaceuticals, University of Melbourne, 13 June 2013
• WO/2013/078500: Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug, Jurox Pty Ltd, 6 June 2013
• WO/2013/075172: Improved synergistic anti-diabetic compositions, Ozstar Therapeutics, 30 May 2013
• WO/2013/071355: Soluble mediator, Walter and Eliza Hall Institute of Medical Research, 23 May 2013
• WO/2013/067578: Modulators of C3a receptors, University of Queensland, 16 May 2013
• WO/2013/059886: PAT-LM1 epitopes and methods for using same, Patrys, 2 May 2013
• WO/2013/057219: Method for improving the stability of purified Factor VIII after reconstitution, CSL Ltd, 25 April 2013
• WO/2013/036998: Treatment of bone diseases, University of Sydney and Nepean Blue Mountains Local Health District, 21 March 2013
• WO/2013/026099: Fn14 binding proteins and uses thereof, Transbio, 28 February 2013
• WO/2013/020183: Immunogenic compositions and methods therefor, University of Queensland, 14 February 2013
• WO/2013/020164: Compounds for treating Respiratory Syncytial Virus infections, Biota, 14 February 2013
• WO/2013/014092: Inhibitory anti-factor XII/XIIa monoclonal antibodies and their uses, CSL Ltd, 31 January 2013
• WO/2013/013273: Modulators of protease activated receptors, University of Queensland, 31 January 2013
• WO/2013/011021: Use of c-Fms antagonists, University of Melbourne and Morphosys, 24 January 2013
• WO/2013/010225: Enzymes for degrading organophosphates, Commonwealth Scientific and Industrial Research Organisation, 24 January 2013
• WO/2013/006917: Disinfecting formulations and uses thereof. Sunnywipes Pty Ltd, 17 January 2013
• WO/2013/003904: Recombinant low virulence Bovine Herpesvirus 1 (BOHV-1) vaccine vectors, Queensland Department of Agriculture, Fisheries and Forestry, and Meat & Livestock Australia Ltd, 10 January 2013
• WO/2013/003895: Combination therapy, Biosceptre International, 10 January 2013
• WO/2012/171057: Antibodies against G-CSFR and uses thereof, CSL Ltd, 20 December 2012
• WO/2012/167309: Macromolecules, Starpharma, 13 December 2012
• WO/2012/166998: Compositions for sequential administration of opioid receptor agonists, QRxPharma, 6 December 2012
• WO/2012/162753: Biocompatible material and uses thereof, University of Sydney, 6 December 2012
• WO/2012/162731: Blood stage malaria vaccine, Griffith University and La Trobe University, 6 December 2012
• WO/2012/155203: Regulation of nitric oxide release and biofilm development, University of New South Wales and University of Wollongong, 22 November 2012
• WO/2012/155172: Method of treatment or prophylaxis of bacterial vaginosis, Starpharma, 22 November 2012
• WO/2012/153126: Therapeutic canine immunoglobulins and methods of using the same, Nexvet, 15 November 2012
• WO/2012/153122: Anti-nerve growth factor antibodies and methods of preparing and using the same, NVIP Pty Ltd, 15 November 2012
• WO/2012/153121: Anti-nerve growth factor antibodies and methods of preparing and using the same, Nexvet, 15 November 2012
• WO/2012/151640: Methods for preparing naphthyridines, Bionomics, 15 November 2012
• WO/2012/142662: Modified variable domain molecules and methods for producing and using them, Garvan Institute of Medical Research, 26 October 2012
• WO/2012/122604: Pharmaceutical compositions and topical use thereof, Regeneus, 20 September 2012
• WO/2012/122590: Antibody recognizing n-domain of midkine, Cellmid, 20 September 2012
• WO/2012/122586: New composition, Phosphagenics and Mastitis Management Australia, 20 September 2012
• WO/2012/119203: Gene expression and eradication system in Helicobacter pylori, Ondek Pty Ltd, 13 September 2012
• WO/2012/116391: Cosmetic or pharmaceutical formulation, Wendy Lien, 7 September 2012
• WO/2012/113017: Control of insect pests, Innovate Ag Pty Ltd, 30 August 2012
• WO/2012/110773: FAK inhibitors, Cancer CRC, 23 August 2012
• WO/2012/109445: Hybrid opioid compounds and compositions, QRxPharma, 16 August 2012
• WO/2012/106761: Sugar extracts, Horizon Science, 16 August 2012
• WO/2012/103588: Treatment of bone marrow edema (oedema) with polysulfated polysaccharides, Paradigm Biopharma, 9 August 2012
• WO/2012/103583: Positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor and uses thereof, Bionomics, 9 August 2012
• WO/2012/096866: Use of beta-adrenergic inverse agonists for smoking cessation, Inverseon, 19 July 2012
• WO/2012/094703: Combination therapy, Dimerix, 19 July 2012
• WO/2012/079121: Improved mineral based composition and methods of use, Tuffrock Technology Pty Ltd, 21 June 2012
• WO/2012/075534: Methods for forming miniemulsions and use thereof for delivering bioactive agents, NS Technologies Pty Ltd, 14 June 2012
• WO/2012/071611: Histone inhibition, Australian National University, 7 June 2012
• WO/2012/068637: Compositions and methods, Macfarlane Burnet Institute for Medical Research and Public Health, 31 May 2012
• WO/2012/068627: Peptides for the specific binding of RNA targets, University of Western Australia, 31 May 2012
• WO/2012/068619: Preparation and/or formulation of proteins cross-linked with polysaccharides, Elastagen, 31 May 2012
• WO/2012/068612: Methods of treating eye diseases associated with inflammation and vascular proliferation, Fibrotech Therapeutics Pty Ltd, 31 May 2012
• WO/2012/061882: Treatment and prevention of malaria, Walter and Eliza Hall Institute of Medical Research, 18 May 2012
• WO/2012/054978: Novel anti-cancer agents, Ludwig Institute for Cancer Research and Walter And Eliza Hall Institute Of Medical Research, 3 May 2012
• WO/2012/052205: Selective targeting of the CD40/Max-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis, Universitätsklinikum Freiburg and Baker IDI Heart and Diabetes Institute, 26 April 2012
• WO/2012/037612: Novel immunostimulatory method, University of Melbourne, 29 March 2012
• WO/2012/037239: Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia, QRxPharma, 22 March 2012
• WO/2012/035558: A synthetic immunogen useful for generating long lasting immunity and protection against pathogens, Council Of Scientific & Industrial Research and University Of Melbourne, 22 March 2012
• WO/2012/034194: Method for mobilizing stem and/or progenitor cells, Antisense Therapeutics, 22 March 2012
• WO/2012/031333: Companion animal treatments, Biosceptre International, 15 March 2012
• WO/2012/031326: Single chain relaxin polypeptides, Howard Florey Institute of Experimental Physiology and Medicine and University Of Queensland, 15 March 2012
• WO/2012/023051: Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder, Immuron, 23 February 2012
• WO/2012/021942: TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease, Florey Institute of Neuroscience and Mental Health, 23 February 2012
• WO/2012/021934: Humanized anti-interleukin 3 receptor alpha chain antibodies, CSL Ltd, 23 February 2012
• WO/2012/019237: Therapeutic method for treating congestive heart failure, Madeleine Pharmaceuticals Pty Ltd, 16 February 2012
• WO/2012/016290: Modified Hepatitis C Virus proteins, Macfarlane Burnet Institute for Medical Research and Public Health, 9 February 2012
• WO/2012/012851: Recombinant Neisseria meningitidis PorA porin proteins, Griffith University, 2 February 2012
• WO/2012/012843: Modulators of protease activated receptors, University of Queensland, 2 February 2012
• WO/2012/011144: Use of amino acid sequences from Mycobacterium tuberculosis or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom, Cellestis, 26 January 2012
• WO/2012/010843: Salt and solvates of a tetrahydroisoquinoline derivative, Spinifex Pharmaceuticals Pty Ltd, 26 January 2012
• WO/2012/009760: Anti-Il-23 heterodimer specific antibodies, Cephalon Australia Pty Ltd, 26 January 2012
• WO/2012/003544: Protein kinase inhibitors and methods of treatment, Ludwig Institute for Cancer Research and Walter and Eliza Hall Institute of Medical Research, 12 January 2012
• WO/2012/000055: Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease, Brien Holden Vision Institute, 5 January 2012
• WO/2012/000048: A reconstituted High Density Lipoprotein formulation and production method thereof, CSL Ltd, 5 January 2012
• WO/2011/160191: Compound for the treatment of enteroviruses, Biota, 29 December 2011
• WO/2011/160182: Means of controlling infection persistence of Helicobacter pylori, Ondek Pty Ltd, 29 December 2011
• WO/2011/160170: Stimulating immune response, Peter MacCallum Cancer Institute, 29 December 2011
• WO/2011/156860: Immunotherapeutic method involving CD123 (Il-3rα) antibodies and immunostimulating complex, CSL Ltd, 22 December 2011
• WO/2011/153583: Nociceptin mimetics, University of Queensland, 15 December 2011
• WO/2011/150470: Vitronectin:keratinocyte growth factor chimeras, Queensland University of Technology, 8 December 2011
• WO/2011/150457: Haematopoietic prostaglandin D2 synthase inhibitors, University of Queensland, 8 December 2011
• WO/2011/150454: Antibodies directed to the unprocessed receptor tyrosine kinase C-MET, Monash University and Ludwig Institute for Cancer Research, 8 December 2011
• WO/2011/149492: Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases, Genentech and Walter and Eliza Hall Institute of Medical Research, 1 December 2011
• WO/2011/148316: Drug-delivery accessory for an implantable medical device, Cochlear, 1 December 2011
• WO/2011/146981: Anti-diabetic compositions and methods, Ozstar Therapeutics, 1 December 2011
• WO/2011/146978: Delivery of oral care products, International Scientific Pty Ltd, 1 December 2011
• WO/2011/143706: Methods relating to an attenuated mycoplasma, Bioproperties Pty Ltd, 24 November 2011
• WO/2011/140595: Immunostimulatory and vaccine compositions, 4G Vaccines Pty Ltd, 17 November 2011
• WO/2011/127543: Proteins that bind PI16 and uses thereof, Transbio, 20 October 2011
• WO/2011/120084: Transdermal delivery patch, Phosphagenics, 6 October 2011
• WO/2011/112791: Modulating aquaporins with relaxin, University of Melbourne and University of Florida, 15 September 2011
• WO/2011/112549: Temperature sensitive conjugate compositions, and uses related thereto, Emory University and Baker IDI Heart and Diabetes Institute, 15 September 2011
• WO/2011/103633: Treatment or prevention of infection, Oral Health Australia Pty Ltd, 1 September 2011
• WO/2011/103624: Method of treatment or prevention of hair loss or for the enhancement of hair growth, Cellmid, 1 September 2011
• WO/2011/100786: Compositions and methods for targeting type 1 interferon producing cells, CSL Ltd, 25 August 2011
• WO/2011/094823: Compounds for treating Respiratory Syncytial Virus infections, Biota, 11 August 2011
• WO/2011/088504: Methods and compositions for improved nerve conduction velocity, Spinifex Pharmaceuticals Pty Ltd, 28 July 2011
• WO/2011/088503: Anaesthetic formulation, Juliet and Colin Goodchild and Monash University, 28 July 2011
• WO/2011/079349: Okadaella gastrococcus and cancer, Okada Medical Services, 7 July 2011
• WO/2011/075789: Antibodies to non-functional oligomeric p2x7 receptors, Biosceptre International, 30 June 2011
• WO/2011/075786: Immuno-conjugates and methods for producing them 2, Avipep Pty Ltd, 30 June 2011
• WO/2011/075777: Neuronal stimulation, University of Queensland, 30 June 2011
• WO/2011/075766: Antimicrobial compounds, University of Western Australia, 30 June 2011
• WO/2011/069214: Methods and compositions for bone and cartilage repair, Cimtech, 16 June 2011
• WO/2011/069037: Stabilization and storage of biological pharmaceutical compositions, University of North Carolina at Charlotte, Charlotte-Mecklenburg Hospital Authority, Monash University, 9 June 2011
• WO/2011/068560: Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases, AbbVie and Walter Eliza Hall Institute of Medical Research, 9 June 2011
• WO/2011/063477: Fibronectin: growth factor chimeras, Queensland University of Technology, 3 June 2011
• WO/2011/063456: Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors, University of Western Australia, 3 June 2011
• WO/2011/054030: Treatment of cancer involving mutated KRAS or BRAF genes, Cephalon Australia Pty Ltd, 12 May 2011
• WO/2011/047434: A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent, Propanc, 28 April 2011
• WO/2011/044628: Allergy treatment using acid-treated aqueous whey protein extract, Dairy Australia and Women's and Children's Health Research Institute, 21 April 2011
• WO/2011/041847: Chaperonin 10 variants, CBio Ltd, 14 April 2011
• WO/2011/038451: Therapy and prevention of problem drinking, University of Sydney, 7 April 2011
• WO/2011/032233: Novel omega conotoxin peptides, University of Queensland, 24 March 2011
• WO/2011/032204: Treatment of neurological conditions, CSL Ltd, 24 March 2011
• WO/2011/023584: Nano silver-zinc oxide composition, Polymers CRC, 3 March 2011
• WO/2011/022772: Combination therapy for treating proliferative diseases, Bionomics, 3 March 2011
• WO/2011/006204: Method of providing agents to the cochlea, University of New South Wales, 20 January 2011
• WO/2011/003155: Biopolymer hybrid gel-depot delivery system, Polymers CRC, 13 January 2011
• WO/2011/003129: Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers, Ozteo Pty Ltd, 13 January 2011
• WO/2011/000054: Immuno-conjugates and methods for producing them, Avipep Pty Ltd, 6 January 2011
• WO/2011/000053: Medicinal carbohydrates for treatment of respiratory conditions, Australian Biomedical Company Pty Ltd, 6 January 2011
• WO/2010/143936: Composition and method for improving vascular health, Malaysian Palm Oil Board and Commonwealth Scientific and Industrial Research Organisation, 16 December 2010
• WO/2010/139026: Therapeutic and diagnostic molecules, Centenary Institute of Cancer Medicine and Cell Biology, University Of Sydney, Medvet Science Pty Ltd and the Wenkart Foundation, 9 December 2010
• WO/2010/139018: Novel strains of Helicobacter pylori and uses thereof, Ondek Pty Ltd, 9 December 2010
• WO/2010/135781: Methods of treating diseases, Immunaid Pty Ltd, 2 December 2010
• WO/2010/132959: Use of dynamin ring stabilizers, Children's Medical Research Institute and The General Hospital Corporation, 25 November 2010
• WO/2010/132932: A temperature sensitive vaccine strain of Mycoplasma hyopneumoniae and uses thereof, Bioproperties Pty Ltd and University of Melbourne, 25 November 2010
• WO/2010/127408: Dispersants in high-electrolyte solutions, Huntsman Corporation, 11 November 2010
• WO/2010/127396: One or more of Vigna marina, Cocos nucifera L. or Terminalia catappa L. extracts for treating wounds, skin disorders and hair loss, Cimtech, 11 November 2010
• WO/2010/125445: Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders, Pharmaxis, 4 November 2010
• WO/2010/121328: A novel formulation of indomethacin, iCeutica Pty Ltd, 28 October 2010
• WO/2010/118458: A multidose package, course and method of treatment for delivering predetermined multiple doses of a pharmaceutical, iNova Pharmaceuticals (Australia) Pty Ltd, 21 October 2010
• WO/2010/115229: Immunogenic composition and uses thereof, University of Melbourne, 14 October 2010
• WO/2010/111753: Compositions and methods for treatment of aortic fibrosis, Vectus Biosystems, 7 October 2010
• WO/2010/105290: Humanised antibodies with anti-tumour activity, Cephalon Australia Pty Ltd, 23 September 2010
• WO/2010/102337: Injectable biomaterials, University of Sydney, 16 September 2010
• WO/2010/096868: Topical foam composition, Stiefel Research Australia Pty Ltd, 2 September 2010
• WO/2010/094074: Pharmaceutical preparation and delivery system, Palmaya Pty Ltd, 26 August 2010
• WO/2010/094068: Treatment of chronic inflammatory conditions, CSL Ltd and University of Melbourne, 26 August 2010
• WO/2010/078300: Dual functioning ionic liquids and salts thereof, University of Alabama, Monash University, Queen's University Belfast 8 July 2010
• WO/2010/071944: Quinazolinone compounds, Prana Biotechnology, 1 July 2010
• WO/2010/071941: Plant extracts from acronychia species and their use, Ecobiotics, 1 July 2010
• WO/2010/071924: Osteoarthritis treatment, University Of Melbourne, 1 July 2010
• WO/2010/071923: Pain treatment, University of Melbourne, 1 July 2010
• WO/2010/065433: Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate, Novartis and Medvet Science Pty Ltd, 10 June 2010
• WO/2010/063080: Amphiphile prodrugs, Commonwealth Scientific and Industrial Research Organisation, 10 June 2010
• WO/2010/063069: Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals, University of Melbourne, 10 June 2010
• WO/2010/062264: Lipopeptide compounds and their use, UniQuest Pty Ltd, 3 June 2010
• WO/2010/054437: Vaccine strains of Brachyspira hyodysenteriae, Spirogene Pty Ltd, 20 May 2010
• WO/2010/046338: Composition for targeting dendritic cells, Domantis Ltd and Lipotek Pty Ltd, 29 April 2010
• WO/2010/043000: S1P receptors modulators and their use thereof, Akaal Pharma, 22 April 2010
• WO/2010/042997: Compositions and methods for treatment of kidney disorders, Vectus Biosystems, 22 April 2010
• WO/2010/040188: Biodegradable polymer - bioactive moiety conjugates, Bionic Ear Institute, 15 April 2010
• WO/2010/032141: Non-typeable Haemophilus influenzae vaccines and their uses, Hunter Immunology Ltd, 25 March 2010
• WO/2010/028419: Prevention of psychotic disorders and/or treatment of psychotic symptoms, Orygen Research Centre, 18 March 2010
• WO/2010/022463: Prevention, treatment and diagnosis of P. gingivalis infection, Oral Health Australia, 4 March 2010
• WO/2010/022462: Mutant bacterial glycoproteins and uses thereof, University of Queensland, 4 March 2010
• WO/2010/022452: Methods and compositions for treating and preventing malaria using an invasion ligand directed to a protease-resistant receptor, Walter and Eliza Hall Institute of Medical Research, 4 March 2010
• WO/2010/020005: Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes, Regeneus, 25 February 2010
• WO/2010/017598: Anti-Il-12/Il-23 antibodies, Arana Therapeutics, 18 February 2010
• WO/2010/015029: Compositions and methods for treating psychiatric disorders, Gosforth Centre (Holdings) Pty Ltd, 11 February 2010
• WO/2010/015024: Plant anti-pathogen systems, Hexima, 11 February 2010
• WO/2010/006377: Therapeutic agents, Nutripep Pty Ltd, 21 January 2010
• WO/2010/004438: LM antibodies, functional fragments, LM-1 target antigen, and methods for making and using same, Patrys, 14 January 2010
• WO/2010/003193: Peptide inhibitors of CD40L signaling and uses therefor, Phylogica, 14 January 2010
• WO/2010/003191: Biocompatible material and uses thereof, University of Sydney, 14 January 2010
• WO/2010/002867: Multivalent antihelminthic vaccine, Albert B. Sabin Vaccine Institute with QIMR Berghofer Medical Research Institute and George Washington University, 7 January 2010
• WO/2010/000041: Anti-P2X7 peptides and epitopes, Biosceptre International, 7 January 2010
• WO/2010/000011: The use of androgens for vascular regeneration and endothelial repair, Heart Research Institute, 7 January 2010
• WO/2009/152551: Pharmaceutical formulation, Alphapharm Pty Ltd, 23 December 2009
• WO/2009/143572: Methods of treating mammals with eustachian tube dysfunctions, University of Melbourne, 3 December 2009
• WO/2009/143571: Antiviral salts, Biota, 3 December 2009
• WO/2009/137890: Administrable compositions, University of Sydney, 19 November 2009
• WO/2009/137889: Polymer microgel beads, University of Sydney, 19 November 2009
• WO/2009/137888: Polymer microgel beads and preparative method thereof, University of Sydney, 19 November 2009
• WO/2009/137881: Angiogenin-enriched milk fractions, Agriculture Victoria Services Pty Ltd and Murray Goulburn Co-Operative Co. Ltd, 19 November 2009
• WO/2009/137880: Use of angiogenin or angiogenin agonists for treating diseases and disorders, Agriculture Victoria Services Pty Ltd and Murray Goulburn Co-Operative Co. Ltd, 19 November 2009
• WO/2009/129578: Methods for radiolabelling synthetic polymers, Australian National University, 29 October 2009
• WO/2009/129577: Methods for radiolabelling macromolecules, Australian National University, 29 October 2009
• WO/2009/124353: Modified CPN10 and PRR signalling, CBio Ltd, 15 October 2009
• WO/2009/118191: Therapy for vitiligo, Clinuvel Pharmaceuticals, 1 October 2009
• WO/2009/111846: Mitochondrially delivered anti-cancer compounds, Cancure Ltd, 17 September 2009
• WO/2009/108999: Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders, NAD Life Pty Ltd, 11 September 2009
• WO/2009/105824: Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor, Mimetica Pty Ltd, 3 September 2009
• WO/2009/105823: 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists, Mimetica, 3 September 2009
• WO/2009/097735: Use of compounds extracted from Momordica charantia L. in the manufacture of medicaments for prevention and treatment of diabetes and obesity, Shanghai Institute Materia Medica, Chinese Academy of Sciences, Garvan Institute of Medical Research, 13 August 2009
• WO/2009/097660: Patch production, University Of Queensland, 13 August 2009
• WO/2009/097657: Method of producing progenitor cells from differentiated cells, Regenertech Pty Ltd, 13 August 2009
• WO/2009/094730: Vaccine compositions, University of Newcastle, 6 August 2009
• WO/2009/094717: A method of inducing tolerance to an allergen, Murdoch Childrens Research Institute, 6 August 2009
• WO/2009/089593: Process for preparing nutritional, therapeutic or organoleptic products from crude glycerol, Bio Processing Australia Pty Ltd, 23 July 2009
• WO/2009/086596: Method of producing a population of cells, University of Queensland, 16 July 2009
• WO/2009/086591: Diagnostic and therapeutic methods for EFMR (epilepsy and mental retardation limited to females), Medvet Science Pty Ltd, 16 July 2009
• WO/2009/079712: Coating method, University of Queensland, 2 July 2009
• WO/2009/079683: Translocator protein ligands, University of Sydney, 2 July 2009
• WO/2009/073930: Nutraceutical composition and methods of use, Dacy Tech Pty Ltd, 18 June 2009
• WO/2009/073916: Improved treatment and prophylaxis, Mater Medical Research Institute, 18 June 2009
• WO/2009/073911: Treatment and prophylaxis, Mater Medical Research Institute, 18 June 2009
• WO/2009/070847: Compounds for therapy and diagnosis, Prana Biotechnology, 11 June 2009
• WO/2009/070842: Protection of progenitor cells and regulation of their differentiation, Proteobioactives Pty Ltd, 11 June 2009
• WO/2009/067734: Nanoemulsions, Commonwealth Scientific and Industrial Research Organisation, 4 June 2009
• WO/2009/062254: Device and method for preparing microparticles, University of Queensland, 22 May 2009
• WO/2009/061961: Use of Vitamin D receptor agonists and precursors to treat fibrosis, Salk Institute for Biological Studies and University of Sydney , 14 May 2009
• WO/2009/059350: Anti-microbial polymers and their compositions, Recce, 14 May 2009
• WO/2009/055859: Transdermal delivery system for hormones and steroids, Acrux, 7 May 2009
• WO/2009/055854: Chimeric relaxin polypeptides comprising an A and B chain derived from different relaxin family peptides, Florey Institute of Neuroscience and Mental Health, 7 May 2009
• WO/2009/052588: Cytokine muteins, CSL Ltd, 30 April 2009
• WO/2009/052566: Anti-microbial composition, Wild Child, 30 April 2009
• WO/2009/052555: Immunogenic protein Pas n 1 from Bahia grass pollen, University of Queensland and Queensland University of Technology, 30 April 2009
• WO/2009/049350: Expression system for modulating an immune response, University of Queensland, 23 April 2009
• WO/2009/046498: A method of transfection and compositions therefor, University of Melbourne, 16 April 2009
• WO/2009/046497: Method of eliciting an immune response against pandemic influenza virus, CSL Ltd, 16 April 2009
• WO/2009/043111: Composition and method for dermal regeneration, Ultraceuticals R & D Pty Ltd, 9 April 2009
• WO/2009/043107: Treatment of neurological disorders, Velacor Therapeutics Pty Ltd, 9 April 2009
• WO/2009/040507: Substituted benamidines as antibacterial agents, Prolysis Ltd, 2 April 2009
• WO/2009/039567: Molecular delivery vesicle, University of Queensland, 2 April 2009
• WO/2009/036510: Novel avian cytokines and genetic sequences encoding same, Commonwealth Scientific and Industrial Research Organisation and Australian Poultry CRC, 26 March 2009
• WO/2009/033233: Novel P2X7 epitopes, Biosceptre International Ltd, 19 March 2009
• WO/2009/031934: Method for producing vegetable cell sap concentrate and means for the production thereof, Solagran, 12 March 2009
• WO/2009/029991: Agents with angiogenic and wound healing activity, Meat & Livestock Australia Ltd and Industrial Research Ltd, 12 March 2009
• WO/2009/028965: Surgical hydrogel, Robinson Squidgel Ltd, University of Adelaide, University of Otago, 5 March 2009
• WO/2009/026660: Dendritic cell marker and uses thereof, Walter and Eliza Hall Institute of Medical Research and Burnet Institute, 5 March 2009
• WO/2009/021288: Improved gene silencing methods, Commonwealth Scientific and Industrial Research Organisation, 19 February 2009
• WO/2009/021276: Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof, University of Technology, Sydney, 19 February 2009
• WO/2009/006700: Immunology treatment for biofilms, Oral Health Australia Pty Ltd, 15 January 2009
• WO/2009/006699: Biofilm treatment, Oral Health Australia Pty Ltd, 15 January 2009
• WO/2009/003226: Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration, Phovitreal Pty Ltd, 8 January 2009
• WO/2008/154700: Compositions and uses thereof for the treatment of Acute Respiratory Distress Syndrome (ARDS) and clinical disorders associated with therewith, Phylogica, 24 December 2008
• WO/2008/148174: Wound repair composition and method, Queensland University of Technology, 11 December 2008
• WO/2008/148166: Clostridial toxin NetB, Australian Poultry CRC Pty Ltd , 11 December 2008
• WO/2008/124872: Latent neural stem cell population, University of Queensland, 23 October 2008
• WO/2008/119110: Treatment of obesity, Baker Medical Research Institute and Christian-Albrechts-Universitat zu Kiel, 9 October 2008
• WO/2008/112192: EPHA3 antibodies for the treatment of solid tumors, Monash University, Ludwig Institute for Cancer Research and KaloBios Pharmaceuticals, 18 September 2008
• WO/2008/109956: Treatment or prophylaxis of asthma, Hunter Immunology, 18 September 2008
• WO/2008/106731: A target for breast cancer therapy and/or diagnosis, University of Queensland, 12 September 2008
• WO/2008/106721: Compositions and methods for delivery of anti-cancer agents, University of Wollongong, 12 September 2008
• WO/2008/095263: A dosage form containing two or more active pharmaceutical ingredients in different physical forms, Alphapharm Pty Ltd, 14 August 2008
• WO/2008/095253: Treatment of ADHD, Gosforth Centre (Holdings) Pty Ltd, 14 August 2008
• WO/2008/095221: Treatment of ADHD, Gosforth Centre (Holdings) Pty Ltd, 14 August 2008
• WO/2008/093246: VEGF receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis, Vegenics Ltd, 7 August 2008
• WO/2008/089521: Insulin sensitisers and methods of treatment, Verva Pharmaceuticals, 31 July 2008
• WO/2008/083423: Spreading implement, Acrux, 17 July 2008
• WO/2008/080194: Pain-relieving compositions and uses therefor, University of Queensland, 10 July 2008
• WO/2008/064401: Improved peptide composition, Alzhyme Pty Ltd, 5 June 2008
• WO/2008/061299: Method of treating diabetes, Garvan Institute of Medical Research, 29 May 2008
• WO/2008/059616: Antibody recognizing C-domain of midkine, Cellmid, 22 May 2008
• WO/2008/058323: Use of tropoelastin for repair or restoration of tissue, University of Sydney, 22 May 2008
• WO/2008/055310: Process for the preparation of angiogenin, Murray Goulburn Co-Operative Co. Ltd and Agriculture Victoria Services Pty Ltd, 15 May 2008
• WO/2008/052263: Delivery system for remote treatment of an animal, Veterinary Encapsulation Biosciences Pty Ltd, 8 May 2008
• WO/2008/046135: Novel anxiolytic compounds, Bionomics, 24 April 2008
• WO/2008/043157: Compositions and methods for modulating immune responses, University of Queensland, 17 April 2008
• WO/2008/041909: A method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair, Norrfors SARL, 10 April 2008
• WO/2008/040094: Particle formation, University of New South Wales, 10 April 2008
• WO/2008/040060: VLP based vaccine delivery system, University of Queensland, 10 April 2008
• WO/2008/037011: Polycyclic agents for the treatment of Respiratory Syncytial Virus infections, Biota, 3 April 2008
• WO/2008/034180: Extracts derived from sugar cane and a process for their manufacture, Horizon Science Pty Ltd, 27 March 2008
• WO/2008/034161: Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor, Phylogica, 27 March 2008
• WO/2008/031172: Methods and compositions for promoting organ development, Kintan Pty Ltd, 20 March 2008
• WO/2008/025099: Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions, Anthony Scammell, 6 March 2008
• WO/2008/025095: Method of eliciting or inducing an immune response, CSL Ltd and University of Melbourne, 6 March 2008
• WO/2008/025094: Method of treatment of photodermatoses, Clinuvel Pharmaceuticals, 6 March 2008
• WO/2008/025073: Method of modulation of expression of Epidermal Growth Factor Receptor (EGF) involving miRNA, University of Western Australia, 6 March 2008
• WO/2008/022401: Recombinant HCV E2 glycoprotein, Macfarlane Burnet Institute for Medical Research and Public Health, 28 February 2008
• WO/2008/022391: Method for producing antibodies, G2 Inflammation Pty Ltd, 28 February 2008
• WO/2008/017126: Treatment of pulmonary disease conditions, CSL Ltd, 14 February 2008
• WO/2008/017125: Targeted polylysine dendrimer therapeutic agent, Starpharma, 14 February 2008
• WO/2008/017122: Polylysine dendrimer contrast agent, Starpharma and Baker IDI Heart and Diabetes Institute, 14 February 2008
• WO/2008/016314: Myostatin antagonists, Orico Ltd, 7 February 2008
• WO/2008/014563: Methods and compositions for promoting activity of anti-cancer therapies, Oncology Research International Ltd, 7 February 2008
• WO/2008/014555: Method of identifying CD4+CD25+ T cells activated to an antigen which express CD8, University of New South Wales, 7 February 2008
• WO/2008/012695: Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells, EnGeneIC, 31 January 2008
• WO/2008/012682: Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors, Commonwealth Scientific and Industrial Research Organisation and Imugene Ltd, 31 January 2008
• WO/2008/011664: Method of producing a population of cells, University of Queensland, 31 January 2008
• WO/2008/008397: Fatty acid pharmaceutical foam, Stiefel Research Australia Pty Ltd, 17 January 2008
• WO/2008/007224: Foamable suspension gel, Stiefel Research Australia Pty Ltd, 17 January 2008
• WO/2008/003141: Therapeutic compounds, Fibrotech and University of Melbourne, 10 January 2008
• WO/2008/000028: Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease, Oral Health Australia Pty Ltd, 3 January 2008
• WO/2007/147217: Method of treatment of glioma brain tumour, Prana Biotechnology, 27 December 2007
• WO/2007/145987: J-superfamily conotoxin peptides, University of Utah, University of Queensland, Max-Planck Society, 21 December 2007
• WO/2007/143794: Formulation comprising whey protein and hydrolysates for improving muscle recovery, Murray Goulburn Co-Operative Co., 21 December 2007
• WO/2007/137369: Medicinal compositions containing honey, Medihoney Pty Ltd, 6 December 2007
• WO/2007/124541: Cox-2 inhibitor, Cambridge Scientific Pty Ltd , 8 November 2007
• WO/2007/124540: Cytokine mediating composition, Cambridge Scientific Pty Ltd, 8 November 2007
• WO/2007/124529: Modulation of T helper cell-mediated immune responses, Northern Sydney and Central Coast Area Health Service and University of Sydney, 8 November 2007
• WO/2007/121522: Pestivirus species, NSW Department of Primary Industries, 1 November 2007
• WO/2007/120533: Minigene expression cassette, Stanford University and Benitec Biopharma, 25 October 2007
• WO/2007/118276: Method of treatment of Age-related Macular Degeneration (AMD), Prana Biotechnology, 25 October 2007
• WO/2007/118270: Cyclised alpha-conotoxin peptides, University of Queensland, 25 October 2007
• WO/2007/115376: Anti-angiogenic agents and methods of their use, University of Western Australia, KBC Research Foundation, Anna University , 18 October 2007
• WO/2007/112475: A method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same, Alchemia, 11 October 2007
• WO/2007/110631: Binding member for GM-CSF receptor, Medimmune and CSL Ltd, 4 October 2007
• WO/2007/109851: Treatment of neurodegenerative diseases, Velacor Therapeutics Pty Ltd, 4 October 2007
• WO/2007/107758: Antibacterial agents, Biota, 27 September 2007
• WO/2007/106951: Antimicrobial protein, Agriculture Victoria Services Pty Ltd, 27 September 2007
• WO/2007/106949: Tenocyte cell culturing method, University of Western Australia, 27 September 2007
• WO/2007/106944: Contraceptive composition, Starpharma, 27 September 2007
• WO/2007/106938: Method of treatment or prophylaxis inflammatory pain, University of Queensland, 27 September 2007
• WO/2007/104070: Method and composition for treating allergic diseases, Wholesome Biopharm Pty Ltd, 20 September 2007
• WO/2007/101232: Inhibition of JAK2 as a treatment of Pulmonary Arterial Hypertension, Cytopia, 7 September 2007
• WO/2007/098557: Regulation of immune responses by modulation of the function of Antigen Presenting Cells, CBio, 7 September 2007
• WO/2007/093177: Metallothionein-derived peptide fragments, University of Tasmania, 23 August 2007
• WO/2007/090242: Fluoride composition and methods for dental mineralization, University of Melbourne, 16 August 2007
• WO/2007/087689: A method of modulating cellular activity and agents for use therein, CRC for Asthma and Airways, 9 August 2007
• WO/2007/087684: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors, Bionomics, 9 August 2007
• WO/2007/082331: Modified macromolecule, Starpharma, 26 July 2007
• WO/2007/070985: Tiglien-3-one derivatives, QBiotics, 28 June 2007
• WO/2007/070984: Spiroketals, Ecobiotics, 28 June 2007
• WO/2007/070947: Antibacterial agents, Alchemia, 28 June 2007
• WO/2007/068055: A method for preventing reduced feed intake in animals and treatment of disease conditions, Hancroft Pty Ltd, 21 June 2007
• WO/2007/065226: VIP fragments and methods of use, Vectus Biosystems, 14 June 2007
• WO/2007/062469: Methods and compositions for preventing and/or treating pancreatitis, Flinders Technologies Pty Ltd , 7 June 2007
• WO/2007/056829: Multitargeting interfering RNAs having two active strands and methods for their design and use, Johnson & Johnson Research, 24 May 2007
• WO/2007/056813: Pediculicide/ovicide composition, Wild Child, 24 May 2007
• WO/2007/053904: Process to control particle size, Alphapharm Pty Ltd, 18 May 2007
• WO/2007/048202: Methods and compositions for modulating wound repair, Women's & Children's Health Research Institute, University of Adelaide and Australian National University, 3 May 2007
• WO/2007/048190: Macromolecular compounds having controlled stoichiometry, Starpharma, 3 May 2007
• WO/2007/045027: Reduction of side effects from aromatase inhibitors used for treating breast cancer, Chavah Pty Ltd, 26 April 2007
• WO/2007/045009: Microbicidal dendrimer composition delivery system, Starpharma, 26 April 2007
• WO/2007/033419: Composition and method for inhibiting herpesviridae infections, Viratec Pty Ltd, 29 March 2007
• WO/2007/028211: Composition of whey growth factor extract for reducing muscle inflammation, Murray Goulburn Co-Operative Co., 15 March 2007
• WO/2007/028196: Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment, Alchemia, 13 March 2007
• WO/2007/025343: Modified chaperonin 10, CBio, 8 March 2007
• WO/2007/025333: Bacterial delivery of biologically active polypeptides, Commonwealth Scientific and Industrial Research Organisation, 8 March 2007
• WO/2007/022287: Modified VEGF and PDGF with improved angiogenic properties, Ludwig Institute for Cancer Research, 22 February 2007
• WO/2007/012133: Therapeutic protocols using hyaluronan, Alchemia, 1 February 2007
• WO/2007/009166: Modulation of granulosa cell apoptosis, University of Adelaide, 25 January 2007
• WO/2007/006095: Chaperonin 10-induced immunomodulation, CBio, 18 January 2007
• WO/2007/006071: Improved process for the production of a radioactive aerosol, Cyclomedica Australia Pty Ltd, 18 January 2007
• WO/2007/003010: Anticoagulation agent and uses thereof, Baker Medical Research Institute, 11 January 2007
• WO/2006/135985: Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same, Walter and Eliza Hall Institute of Medical Research, 28 December 2006
• WO/2006/135982: Ionic complexes, University of Melbourne, 28 December 2006
• WO/2006/135978: Antiviral compounds and methods, Biotron, 28 December 2006
• WO/2006/135965: Composition for treating skin lesions, Dynamiclear Pty Ltd, 28 December 2006
• WO/2006/133519: Particles comprising a releasable dopant therein, Australian Nuclear Science and Technology Organisation, 21 December 2006
• WO/2006/133518: Particles having hydrophobic material therein, Australian Nuclear Science And Technology Organisation, 21 December 2006
• WO/2006/133506: A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof, Phosphagenics, 21 December 2006
• WO/2006/130913: Dental mineralization, University of Melbourne, 14 December 2006
• WO/2006/130904: Dried formulations of nanoparticle-coated capsules, University of South Australia, 14 December 2006
• WO/2006/129161: Vitamin formulation, Stiefel Research Australia Pty Ltd , 7 December 2006
• WO/2006/128259: Substances having body mass redistribution properties, Horizon Science Pty Ltd, 7 December 2006
• WO/2006/125262: Methods and compositions for regulating biofilm development, Environmental Biotechnology CRC Pty Ltd, 30 November 2006
• WO/2006/122345: Method and composition for use in preparation of a patient for surgery, Novapharm Research, 23 November 2006
• WO/2006/116798: A method of forming an injectable radioactive composition of a carbon encapsulated radioactive particulate, Australian National University, 9 November 2006
• WO/2006/110491: Complementary compositions to reduce blood glucose levels and treat diabetes, Astrum Therapeutics Pty Ltd, 19 October 2006
• WO/2006/105615: Buccal delivery system, Ozpharma Pty Ltd, 12 October 2006
• WO/2006/105597: Variants of Hepatitis B Virus with resistance to anti-viral nucleoside agents and applications thereof, Melbourne Health, St. Vincent's Hospital Melbourne and Austin Health, 12 October 2006
• WO/2006/096931: Renal repair and regeneration, University Of Queensland and Monash University, 21 September 2006
• WO/2006/096914: A topical analgesic composition, Animal Ethics Pty Ltd, 21 September 2006
• WO/2006/096905: Control of sucking lice, Microbial Products Pty Ltd, 21 September 2006
• WO/2006/094357: Flavonoid compounds and uses thereof, Howard Florey Institute pf Experimental Physiology and Medicine, and Neuprotect Pty Ltd, 14 September 2006
• WO/2006/094347: Bicyclic nucleosides and nucleotides as therapeutic agents, Biota, 14 September 2006
• WO/2006/089348: Anti-microbial agent, Kayban Pty Ltd, 31 August 2006
• WO/2006/086821: Antisense modulation of integrin α4 expression, Antisense Therapeutics, 24 August 2006
• WO/2006/084339: Layered nanoparticles, Australian Nuclear Science & Technology Organisation, 17 August 2006
• WO/2006/084334: Analgesic and anti-inflammatory composition, Cambridge Scientific Pty Ltd, 17 August 2006
• WO/2006/081620: CD4+ CD25+ T-cells activated to a specific antigen, University of New South Wales, 10 August 2006
• WO/2006/069422: Method and means for improving bowel health, Commonwealth Scientific and Industrial Research Organisation and Biogemma, 6 July 2006
• WO/2006/066361: Method of treatment or prophylaxis, University of Queensland, 29 June 2006
• WO/2006/066354: Formula ions and treatments for well-being, Dolphst Pty Ltd, 29 June 2006
• WO/2006/066323: Formulations and treatments for trichology, Dolphst Pty Ltd, 29 June 2006
• WO/2006/066317: Controlled release of biological entities, Australian Nuclear Science & Technology Organisation, 29 June 2006
• WO/2006/063415: Regulation of metalloprotease cleavage of cell surface proteins, Monash University and Memorial Sloan Kettering Cancer Center, 22 June 2006
• WO/2006/062087: Composition for treating or preventing myocardial disorder or heart failure, Cellmid and Nagoya University, 15 June 2006
• WO/2006/060871: Binding partners of antibodies specific for dendritic cell antigens, Mater Medical Research Institute, 15 June 2006
• WO/2006/060853: Treatment for cancer, University of New South Wales, 15 June 2006
• WO/2006/056027: Human Cytomegalovirus immunotherapy, QIMR Berghofer Medical Research Institute, 1 June 2006
• WO/2006/056013: Stabilized calcium phosphate complexes, University Of Melbourne, 1 June 2006
• WO/2006/047830: Arthrospira-based compositions and uses thereof, Biovite Australia Pty Ltd, 11 May 2006
• WO/2006/045152: Improved tabletting process, Mayne Pharma International Pty Ltd, 4 May 2006
• WO/2006/037188: Compositions and methods for inducing melanogenesis in a subject, Clinuvel Pharmaceuticals, 13 April 2006
• WO/2006/036074: Myostatin isoform, Orico Ltd, 6 April 2006
• WO/2006/034545: Variants of Hepatitis B Virus with resistance to anti-viral nucleoside agents and applications thereof, Melbourne Health and Fundación para la Investifación y Educación en SIDA, 6 April 2006
• WO/2006/032104: Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection, University of Melbourne, 30 March 2006
• WO/2006/032085: Substituted chroman derivatives, medicaments and use in therapy, Novogen, 30 March 2006
• WO/2006/024100: New polymorphic form of inulin and uses thereof, Vaxine Pty Ltd, 9 March 2006
• WO/2006/024092: VEGF inhibition, University of New South Wales, 9 March 2006
• WO/2006/021894: Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells, EnGeneIC, 2 March 2006
• WO/2006/018743: Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder, Biolog Health Solutions Pty Ltd and Tracey Seipel, 23 February 2006
• WO/2006/017914: Methods and compositions for treatment of hematologic cancers, Viralytics, 23 February 2006
• WO/2006/017896: Metabolism-modulating agents and uses therefor, University of Queensland, 23 February 2006
• WO/2006/017895: Oral killed vaccines and method for providing same, Hunter Immunology Pty Ltd, 23 February 2006
• WO/2006/015445: Bacterial delivery system, Barry Marshall, 16 February 2006
• WO/2006/012688: A method of treating cancer comprising a VEGF-B antagonist, CSL Ltd, 9 February 2006
• WO/2006/012667: Methods of inducing melanogenesis in a subject, Clinuvel Pharmaceuticals, 9 February 2006
• WO/2006/010221: A colour compensating system, Blonde Holdings Pty Ltd, 2 February 2006
• WO/2006/007667: Therapeutic and diagnostic agents, Walter and Eliza Hall Institute of Medical Research, 26 January 2006
• WO/2006/002493: An echinacea formulation, Mediherb Holdings Ltd, 12 January 2006
• WO/2005/120545: Compositions and methods for treatment of cardiovascular disease, Vectus Biosystems, 22 December 2005
• WO/2005/117608: Natural sweetener, Horizon Science Pty Ltd, 15 December 2005
• WO/2005/115430: Treatment of inflammatory airway disease, GroPep, 8 December 2005
• WO/2005/115345: Oral therapeutic compound delivery system, Imaginot Pty Ltd , 8 December 2005
• WO/2005/113004: Small molecule inhibitors for MRP1 and other multidrug transporters, Cleveland Clinic and University of New South Wales, 1 December 2005
• WO/2005/108430: Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent, Scancell Ltd, 17 November 2005
• WO/2005/105132: Methods for preventing or treating bone disorders, Metabolic Pharmaceuticals, 10 November 2005
• WO/2005/100374: Therapeutic heparins and their binding to interleukins 4 and 5, and PECAM-1, Curtin University of Technology, 27 October 2005
• WO/2005/099746: Method for modulating appetite, St Vincent's Hospital Sydney, 27 October 2005
• WO/2005/097094: Antimicrobial compositions and methods for their use, Dermcare-Vet Pty Ltd, 20 October 2005
• WO/2005/094162: Culture and use of cells that secrete liver secretory factors, Fac8Cell Pty Ltd, 13 October 2005
• WO/2005/090388: Alpha helical mimics, their uses and methods for their production, University of Queensland, 29 September 2005
• WO/2005/089778: Biodegradable polyurethane and polyurethane ureas, Commonwealth Scientific and Industrial Research Organisation, 29 September 2005
• WO/2005/087931: Modified oncolytic viruses, Viralytics, 22 September 2005
• WO/2005/087926: Multiple promoter expression cassettes for simultaneous delivery of RNAi agents, Benitec Biopharma, 22 September 2005
• WO/2005/087808: Growth factor binding constructs materials and methods, Ludwig Institute for Cancer Research, 22 September 2005
• WO/2005/087177: Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same, Ludwig Institute for Cancer Research, 22 September 2005
• WO/2005/084678: Alkaloid formulations, Vital Health Sciences Pty Ltd, 15 September 2005
• WO/2005/082894: Cell targeting conjugates, Peter MacCallum Cancer Centre, 9 September 2005
• WO/2005/081854: EGF receptor epitope peptides and uses thereof, Commonwealth Scientific and Industrial Research Organization, Ludwig Institute for Cancer Research and Massachusetts Institute of Technology, 9 September 2005
• WO/2005/079854: Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells, EnGeneIC, 1 September 2005
• WO/2005/077299: Isolated plasma and method for hyperimmunisation and plasma collection, Plasma Ventures Pty Ltd, 25 August 2005
• WO/2005/067959: Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion, CBio, 28 July 2005
• WO/2005/063991: Live genetically attenuated malaria vaccine, Seattle Biomedical Research Institute and Heidelberg University, 14 July 2005
• WO/2005/061513: Polycyclic agents for the treatment of Respiratory Syncytial Virus infections, Biota, 7 July 2005
• WO/2005/060739: Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5aR, G2 Inflammation Pty Ltd, 7 July 2005
• WO/2005/058344: Antimicrobial composition, University of Melbourne, 30 June 2005
• WO/2005/058319: Methods and compositions, CNSBio Pty Ltd, 30 June 2005
• WO/2005/056749: Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells, EnGeneIC, 23 June 2005
• WO/2005/049635: Human monoclonal antibody having fat-reducing effect, Peter Vollmers, 2 June 2005
• WO/2005/048998: GI tract delivery systems, Commonwealth Scientific and Industrial Research Organisation, 2 June 2005
• WO/2005/048967: A method of inducing melanogenesis in humans with MC1R variant alleles, Clinuvel Pharmaceuticals, 2 June 2005
• WO/2005/047332: Adenocarcinoma specific antibody SAM-6, and uses thereof, Patrys, 26 May 2005
• WO/2005/044874: Method of manufacture of polyacrolein, Chemeq, 19 May 2005
• WO/2005/042733: HBV variants detection and application, Melbourne Health, Austin Health, Southern Health, Bayside Health and St. Vincent's Hospital Melbourne, 12 May 2005
• WO/2005/040816: Method of therapy, Immunaid Pty Ltd, 6 May 2005
• WO/2005/037308: Methods and agents for the treatment of cancer, Inter-K Pty Ltd, 28 April 2005
• WO/2005/037293: Immunomodulating compositions and uses therefor, Griffith University and Monash University, 28 April 2005
• WO/2005/035548: The modulation of hyaluronan synthesis and degradation in the treatment of disease, Alchemia, 21 April 2005
• WO/2005/034871: Methods for treating diseases and conditions with inverse agonists, Invion, 21 April 2005
• WO/2005/033077: Sequence selective pyrrole and imidazole polyamide metallocomplexes, University of Western Sydney, 14 April 2005
• WO/2005/032578: Therapeutic method, Monash University, 14 April 2005
• WO/2005/030229: Probiotic storage and delivery, Commonwealth Scientific and Industrial Research Organisation, 7 April 2005
• WO/2005/030205: Ocular solutions containing a macrolide antibiotic and/or mycophenolic acid, Advanced Ocular Systems, 7 April 2005
• WO/2005/025621: Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness, QRxPharma, 24 March 2005
• WO/2005/025602: Methods for identifying modulators of protein kinase c-epsilon, Garvan Institute of Medical Research, 24 March 2005
• WO/2005/020997: Compositions for veterinary and medical applications, Australian Biomedical Company Pty Ltd, 10 March 2005
• WO/2005/019440: Methods for enhancing embryo viability, Northern Sydney and Central Coast Area Health Service, 3 March 2005
• WO/2005/018665: Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including Plasmodium spp, McGill University and QIMR Berghofer Medical Research Institute, 3 March 2005
• WO/2005/012508: Skin regeneration system, Queensland University of Technology, 10 February 2005
• WO/2005/012251: Therapeutic agent for chronic obstructive pulmonary disease and method of treatment for Chronic Obstructive Pulmonary Disease with the same, Mariposa Health, 10 February 2005
• WO/2005/011813: Treatment of ocular disease, Gholam Peyman , 10 February 2005
• WO/2005/011724: A method of producing an anticoagulation effect, Cryptome Pharmaceuticals, 10 February 2005
• WO/2005/007188: Methods and compositions for controlling ectoparasites, Hatchtech Pty Ltd, 27 January 2005
• WO/2004/113507: Pharmaceutically compatible method for purifying intact bacterial minicells, EnGeneIC, 29 December 2004
• WO/2004/110475: Connective tissue derived polypeptides, Proteobioactives Pty Ltd, 23 December 2004
• WO/2004/092387: Viral vectors expressing fusion of viral large envelope protein and protein of interest, Hepgenics Pty Ltd, 28 October 2004
• WO/2004/092223: Cross-linked polysaccharide composition, Ultraceuticals R & D Pty Ltd, 28 October 2004
• WO/2004/088322: Multiplex screening for Lysosomal Storage Disorders (LSDs), Women's and Children's Hospital, 14 October 2004
• WO/2004/078922: Modulation of growth hormone receptor expression and insulin-like growth factor expression, Antisense Pharmaceuticals, 16 September 2004
• WO/2004/078210: Preventive for adhesion following abdominal surgery, Cellmid, 16 September 2004
• WO/2004/078209: Composition and method for the treatment and prevention of enteric bacterial infections, Immuron, 16 September 2004
• WO/2004/073739: A method of diagnosis and treatment, Medvet Science Pty Ltd, 2 September 2004
• WO/2004/072284: Modulation of Insulin like Growth Factor I receptor expression, Antisense Therapeutics, 26 August 2004
• WO/2004/071479: Film foaming hydroalcoholic foam, Connetics Australia Pty Ltd, 26 August 2004
• WO/2004/069871: Growth factor complexes and modulation of cell migration and growth, Queensland University of Technology, 19 August 2004
• WO/2004/064833: Clindamycin phosphate foam, Connetics Australia Pty Ltd, 5 August 2004
• WO/2004/064822: Method of inhibiting prostate cancer cell proliferation, Kieran Scott, Garry Graham and Qihan Dong, 5 August 2004
• WO/2004/054613: A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis, Viralytics, 1 July 2004
• WO/2004/050690: Novel χ-Conotoxin peptides - I, Xenome, 17 June 2004
• WO/2004/050688: Novel χ-Conotoxin peptides - II, Xenome, 17 June 2004
• WO/2004/050056: Cochlear implant drug delivery device, Cochlear, 17 June 2004
• WO/2004/043480: Intraocular administration of Cyclosporin A for the treatment of macular degeneration, retinopathy or retinitis pigmentosa, Gholam Peyman, 27 May 2004
• WO/2004/042079: Induction of the mitochondrial permeability transition, University of New South Wales, 21 May 2004
• WO/2004/041300: Chaperonin 10 immunosuppression, CBio, 21 May 2004
• WO/2004/039793: Aminated isoflavonoid derivatives and uses thereof, Novogen, 13 May 2004
• WO/2004/035079: Treatment of osteoarthritis, University of Queensland, 29 April 2004
• WO/2004/035078: Treatment of inflammatory bowel disease, University of Queensland, 29 April 2004
• WO/2004/035062: Carbohydrate based anti-bacterials, Alchemia, 29 April 2004
• WO/2004/032940: Classes of compounds that interact with GPCRs, Alchemia, 22 April 2004
• WO/2004/031161: Neurologically-active compounds, Prana Biotechnology, 15 April 2004
• WO/2004/030662: Combination chemotherapy compositions and methods, Novogen, 15 April 2004
• WO/2004/024773: Methods for regulating cancer, Queen Elizabeth Hospital Research Foundation, 25 March 2004
• WO/2004/022572: Compounds that interact with kinases, Alchemia, 18 March 2004
• WO/2004/016101: Compositions comprising dietary fat complexer and methods for their use, Catherine Jen and Joseph Artiss, 26 February 2004
• WO/2004/014957: Novel immunogenic lipopeptides comprising T-helper and Cytotoxic T Lymphocyte (CTL) epitopes, QIMR Berghofer Medical Research Institute, 19 February 2004
• WO/2004/014956: Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes, QIMR Berghofer Medical Research Institute, 19 February 2004
• WO/2004/014432: Carrier, Vital Health Sciences Pty Ltd, 19 February 2004
• WO/2004/014159: Method of lowering glycaemic index of foods, Queen Bioactives Pty Ltd , 19 February 2004
• WO/2004/011026: Immunogenic compositions and diagnostic and therapeutic uses thereof, Walter and Eliza Hall Institute of Medical Research, 5 February 2004
• WO/2004/009773: Methods and compositions for activating or inhibiting VEGF-D and VEGF-C, Ludwig Institute for Cancer Research, 29 January 2004
• WO/2004/009227: Biodegradable polyurethane/urea compositions, Commonwealth Scientific and Industrial Research Organisation, 29 January 2004
• WO/2004/009035: Compositions and products containing enantiomeric equol, and methods for their making, Childrens Hospital Medical Center and Australian Health & Nutrition, 29 January 2004
• WO/2004/008887: Fruit and/or vegetable derived composition, Phoenix Eagle Company Pty Ltd, 29 January 2004
• WO/2004/007543: Altered Insulin-like Growth Factor binding proteins, University of Adelaide, 22 January 2004
• WO/2004/007461: 8-hydroxy quinoline derivatives, Prana Biotechnology, 22 January 2004
• WO/2004/005351: Neoplasm specific antibodies and uses thereof, Patrys, 15 January 2004
• WO/2004/003161: Immunogenic Mycoplasma hyopneumoniae polypeptides, University of Iowa and NSW Department of Agriculture, 8 January 2004
• WO/2004/001022: Probiotic Propionibacterium jensenii 702, University of Newcastle, 31 December 2003
• WO/2004/000263: Transdermal delivery rate control using amorphous pharmaceutical compositions, Acrux, 31 December 2003
• WO/2003/104203: Therapeutic molecules and methods-1, Cortical Pty Ltd, 18 December 2003
• WO/2003/099811: Kinase inhibitors, Cytopia, 4 December 2003
• WO/2003/095421: Amino acid analogues, Mimotopes Pty Ltd and Baker Medical Research Institute, 20 November 2003
• WO/2003/086448: Use of c5a receptor antagonist in the treatment of fibrosis, Promics Pty Ltd, 23 October 2003
• WO/2003/082914: Prothrombin activating protein, University of Queensland, 9 October 2003
• WO/2003/075670: Treatment and prevention of inflammatory disorders, Monsanto, 8 September 2003
• WO/2003/072114: Vascular therapeutics, University of New South Wales, 4 September 2003
• WO/2003/066841: Viral variants with altered susceptibility to nucleoside analogs and uses thereof, Melbourne Health, Austin and Repatriation Medical Centre and Southern Health , 14 August 2003
• WO/2003/062279: Nutraceuticals for the treatment, protection and restoration of connective tissues, Institute of Nutraceutical Research Pty Ltd, 31 July 2003
• WO/2003/062278: Monoclonal antibodies against extracellular loops of C5aR, G2 Therapies, 31 July 2003
• WO/2003/061767: Methods and compositions for the treatment of asthma and related disorders, Atopic Pty Ltd, 31 July 2003
• WO/2003/055514: Compositions comprising immunoreactive reagents and saponins, and methods of use thereof, CSL Ltd, 10 July 2003
• WO/2003/049730: Treatment of statin side effects using uridine derivatives, Magral Ltd, 19 June 2003
• WO/2003/040138: Dimeric compounds and their use as anti-viral agents, Biota, 15 May 2003
• WO/2003/040137: Dimeric compounds and their use as anti-viral agents, Biota, 15 May 2003
• WO/2003/040136: Dimeric compounds and their use as anti-viral agents, Biota, 15 May 2003
• WO/2003/039564: Selective targeting of apoptotic cells, University of New South Wales, 15 May 2003
• WO/2003/033528: Cyclic peptides as G-Protein Coupled Receptor antagonists, University of Queensland, 24 April 2003
• WO/2003/030930: Human 3 relaxin, Florey Institute of Neuroscience and Mental Health, 17 April 2003
• WO/2003/026681: Inactivation of papillomavirus, Jenny McCloskey, 3 April 2003
• WO/2003/025009: Recombinant allergen with reduced IgE binding but undiminished T-cell antigenicity, University of Melbourne, 27 March 2003
• WO/2003/020762: Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions, Biosceptre International, 13 March 2003
• WO/2003/018781: Regulation of cytotrophoblast cell differentiation and cell migration, University of Adelaide, 6 March 2003
• WO/2003/018069: Preparation and diabetic use of gibberellins, Australian Biomedical Company Pty Ltd, 6 March 2003
• WO/2003/014122: Derivatives of morphine-like opioid compounds, Polychip Pharmaceuticals Pty Ltd and Monash University, 20 February 2003
• WO/2003/011303: Dermal therapy using phosphate derivatives of electron transfer agents, Vital Health Sciences Pty Ltd, 13 February 2003
• WO/2003/006691: Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells, Johnson & Johnson Research, 23 January 2003
• WO/2003/006073: A composition and uses therefor for combating hangover, Penam Investments Pty Ltd, 23 January 2003
• WO/2003/004684: Nucleic acids encoding a recombinant 250 kDa antigen from sporozoites/merozoites of Eimeria maxima and their uses, David Witcombe, Nicholas Smith and Michael Wallach, 16 January 2003
• WO/2003/004644: Delivery of dsRNA to arthropods, Commonwealth Scientific and Industrial Research Organisation, 16 January 2003
• WO/2003/004056: Method for treating Multiple Myeloma, Pacmab Pty Ltd, 16 January 2003
• WO/2003/002594: Hypoglycaemic peptides and methods of use thereof, International Diabetes Institute and Monash University, 9 January 2003
• WO/2003/002545: Peptoid compounds, University of Wollongong, 9 January 2003
• WO/2003/000899: Mutant forms of EtxB and CtxB and their use as carriers, University of Bristol, 3 January 2003
• WO/2003/000736: Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin, Agen Biomedical, 3 January 2003
• WO/2002/102999: Attenuated circovirus, University of Melbourne, 27 December 2002
• WO/2002/102789: Antimicrobial and radioprotective compounds, BioDiem, 27 December 2002
• WO/2002/100445: Treatment and composition for wound healing, University of Sydney, 19 December 2002
• WO/2002/098921: Recombinant antibodies against Infectious Bursal Disease Virus (IBDV), Commonwealth Scientific and Industrial Research Organisation, 12 December 2002
• WO/2002/097094: Bcl-2-Modifying Factor (BMF) sequences and their use in modulating apoptosis, Walter and Eliza Hall Institute of Medical Research, 5 December 2002
• WO/2002/097067: A method of purification of cells, Walter and Eliza Hall Institute of Medical Research, 5 December 2002
• WO/2002/096949: Antigen targeting, QIMR Berghofer Medical Research Institute, 5 December 2002
• WO/2002/094204: Dental restorative materials, University of Melbourne, 28 November 2002
• WO/2002/092126: Binding member which binds to both Lewis y and Lewis b haptens, and its use for treating cancer, Scancell, 21 November 2002
• WO/2002/089587: Methods and compositions for controlling pests, Bioprospect and University of Western Sydney, 14 November 2002
• WO/2002/088184: A molecular marker, Murdoch Children's Research Institute, 7 November 2002
• WO/2002/083181: Novel compositions and uses therefor, University of Queensland, 24 October 2002
• WO/2002/079299: Agent for the prevention and treatment of sexually transmitted diseases - I, Starpharma, 10 October 2002
• WO/2002/079236: Alpha conotoxin peptides with analgesic properties, Bruce Livett, Zeinab Khalil, Kenwyn Gayler and John Down, 10 October 2002
• WO/2002/077033: Antibodies against cancer, Austin Research Institute, 3 October 2002
• WO/2002/074305: Use of a substantially cell membrane impermeable compound for treating arthritis, University of New South Wales, 26 September 2002
• WO/2002/062351: A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis, Royal Alexandra Hospital for Children, 15 August 2002
• WO/2002/061081: A novel gene BNO1 mapping to chromosome 16q24.3, Bionomics, 8 August 2002
• WO/2002/060950: FLT4 (FEGFR-3) as a target for tumor imaging and anti-tumor therapy, Ludwig Institute for Cancer Research, 8 August 2002
• WO/2002/060927: Protein kinase signalling, Cytopia, 8 August 2002
• WO/2002/057306: Antibodies to non-functional P2X7 receptor diagnosis and treatment of cancers and other conditions, BioScceptre International Ltd, 25 July 2002
• WO/2002/057299: VEGFR-3 binding peptides and their use for inhibiting angiogenesis, Ludwig Institute for Cancer Research, 25 July 2002
• WO/2002/055547: sRFP and peptide motifs that interact with sFRP and methods of their use, US Department of Health and Human Services and St Vincents Institute of Medical Research, 18 July 2002
• WO/2002/053572: Delivery systems, Alchemia, 11 July 2002
• WO/2002/051993: MAP kinase integrin-binding domain, University of Newcastle, 4 July 2002
• WO/2002/050096: Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus, Bionomics, 27 June 2002
• WO/2002/050089: Method for purification of lactose, University of Western Sydney, Dairy Research and Development Corporation, Commonwealth Scientific and Industrial Research Organisation and Australian Food Industry Science Centre, 27 June 2002
• WO/2002/050045: Antiviral agents, Biota, 27 June 2002
• WO/2002/044216: Probes for identifying cancer-specific antigens, Cancerprobe Pty Ltd, 6 June 2002
• WO/2002/041901: Treatment of osteoporosis, Arthropharm Pty Ltd , 30 May 2002
• WO/2002/040033: Formulation containing phosphate derivatives of electron transfer agents, Vital Health Sciences Pty Ltd, 23 May 2002
• WO/2002/038594: Novel therapeutic compositions for treating infection by Lawsonia spp, Agriculture Victoria Services Pty Ltd, Australian Pork Ltd and Pfizer, 16 May 2002
• WO/2002/036784: Transgenic animals for analysing cyp3a4 cytochrome p450 gene regulation, University of Sydney, 10 May 2002
• WO/2002/034900: Dipeptidyl peptidases, University of Sydney, 2 May 2002
• WO/2002/034299: Inorganic low density radionuclide coated particles, Sirtex Medical, 2 May 2002
• WO/2002/034298: Low density radionuclide-containing particulate material, Sirtex Medical, 2 May 2002
• WO/2002/024219: Growth factor complex, Queensland University of Technology, 28 March 2002
• WO/2002/022164: Composition comprising immunogenic microparticles, Austin Research Institute, 21 March 2002
• WO/2002/017971: Slow release pharmaceutical preparation and method of administering same, Palmaya Pty Ltd, 7 March 2002
• WO/2002/015914: Vascularised tissue graft, Bernard O'Brien Institute of Microsurgery, 28 February 2002
• WO/2002/010341: Microsporidia isolate, University of Technology Sydney, 7 February 2002
• WO/2002/007682: Methods for treating atopic disorders, John Vyden, 31 January 2002
• WO/2002/005852: Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease, Alchemia, 24 January 2002
• WO/2002/005828: Compositions and methods for the treatment of skin damage, Gropep, 24 January 2002
• WO/2002/000245: Neurotoxic oligomers, Prana Biotechnology and Massachusetts General Hospital, 3 January 2002
• WO/2001/097836: Compositions and methods for treatment of candidiasis, Candivax Pty Ltd, 27 December 2001
• WO/2001/094559: Hepatitis B Virus DNA polymerase and surface antigen variants and methods of using same, Melbourne Health, University of Hong Kong, Austin and Repatriation Medical Centre and Central Sydney Area Health Service, 13 December 2001
• WO/2001/093912: Vaccine, Austin Research Institute and University of Melbourne , 13 December 2001
• WO/2001/093885: Therapeutic agents - II, Peplin Biotech, 13 December 2001
• WO/2001/090197: Synthetic peptides and uses therefore, Australian National University, 29 November 2001
• WO/2001/088097: Immune potentiating compositions, Monash University and Griffith University, 22 November 2001
• WO/2001/087332: Compositions and methods for treatment of mucosal infections, Hunter Immunology Ltd, 22 November 2001
• WO/2001/083530: Porphyromonas gingivalis recombinant proteins and truncations, CSL Ltd, 8 November 2001
• WO/2001/083519: Antigenic peptide fragments of VAPA protein, and uses thereof, University of South Australia, Medvet Science Pty Ltd and Rural Industries Research and Development Corporation, 8 November 2001
• WO/2001/081928: Diagnostic assay and method of treatment involving Macrophage Inhibitory Cytokine -1 (MIC-1), St Vincent's Hospital Sydney, 1 November 2001
• WO/2001/076594: Antimicrobial coatings, University of New South Wales, 18 October 2001
• WO/2001/073078: A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide, Macfarlane Burnet Institute for Medical Research and Public Health, 4 October 2001
• WO/2001/072310: Pharmaceutical gel composition, Chiltern Pharmaceuticals Pty Ltd , 4 October 2001
• WO/2001/070755: Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents, Australian Nuclear Science & Technology Organisation , 27 September 2001
• WO/2001/070234: Anaesthetic composition, Jurox Pty Ltd, 27 September 2001
• WO/2001/062942: Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators, Ludwig Institute for Cancer Research, 30 August 2001
• WO/2001/062281: PAI-2 conjugates for the treatment and imaging of cancer, University of Wollongong, Medical Scitec Australia Pty Ltd and Biotech Australia Pty Ltd, 30 August 2001
• WO/2001/062232: Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use, Australian Nuclear Science & Technology Organisation, 30 August 2001
• WO/2001/060979: Pancreatic islet cell growth factors, Walter and Eliza Hall Institute of Medical Research , 23 August 2001
• WO/2001/055182: Proteins comprising conserved regions of Neisseria meningitidis surface antigen NhhA, University of Queensland, 2 August 2001
• WO/2001/052871: Preparation and xenotransplantation of porcine islets, Diatranz, 26 July 2001
• WO/2001/052844: Brain, spinal, and nerve injury treatment, Eustralis Pharmaceuticals, 26 July 2001
• WO/2001/047961: P. gingivalis antigenic composition, CSL Ltd, 5 July 2001
• WO/2001/047492: Improved pharmaceutical compositions for poorly soluble drugs, F H Faulding & Co., 5 July 2001
• WO/2001/042301: Interferon-alpha induced gene, Pharma Pacific Pty Ltd, 14 June 2001
• WO/2001/038374: Tumour suppressor factor, University of Western Australia, 31 May 2001
• WO/2001/037866: A method of treating a malignancy in a subject and a pharmaceutical composition for use in same, Viralytics, 31 May 2001
• WO/2001/033977: Product and method for control of obesity, Metabolic Pharmaceuticals, 17 May 2001
• WO/2001/029198: Polypeptide fragments comprising c-terminal portion of Helicobacter catalase, Chris Doidge, Elizabeth Webb, Linda Rothel, Philip Sutton and Stuart Hazell, 26 April 2001
• WO/2001/029079: Immuno-interactive fragments of the αC subunit of inhibin, Prince Henry's Institute of Medical Research, 26 April 2001
• WO/2001/027157: A biologically active complex of NR6 and cardiotrophin-like-cytokine, Amrad, 19 April 2001
• WO/2001/027132: Estradiol conjugates and uses thereof, University of Melbourne , 19 April 2001
• WO/2001/021172: Anti-cancer nitro- and thia-fatty acids, Women's and Children's Hospital Adelaide , 29 March 2001
• WO/2001/019960: Recombinant microorganisms expressing an oligosaccharide receptor mimic, Women's and Children's Hospital and Luminis Pty Ltd, 22 March 2001
• WO/2001/019866: Dipeptidyl peptidases, University of Sydney, 22 March 2001
• WO/2001/019822: Antiviral agents, Biota, 22 March 2001
• WO/2001/017530: Iron chelators and uses thereof, Heart Research Institute and University of Queensland , 15 March 2001
• WO/2001/016172: Vaccine antigens of Moraxella, Commonwealth Scientific and Industrial Research Organisation and University of Melbourne, 8 March 2001
• WO/2001/012179: Ophthalmic fluid, Planned Products Pty Ltd, 22 February 2001
• WO/2001/007442: Beta-amyloid peptide inhibitors, Biomolecular Research Institute and University of Melbourne, 1 February 2001
• WO/2001/005410: Neurotropic virus transport, Westmead Hospital and University of Sydney , 25 January 2001
• WO/2001/002008: Control of acidosis, University of New England, 11 January 2001
• WO/2000/078341: A method for the prophylaxis and/or treatment of medical disorders, Murdoch Children's Research Institute , 28 December 2000
• WO/2000/072875: A method of prophylaxis and treatment and agents useful for same, University of Sydney, 7 December 2000
• WO/2000/069906: Lawsonia derived gene and related hemolysin polypeptides, peptides and proteins and their uses, Pfizer, Agriculture Victoria Services Pty Ltd and Australian Pork Ltd, 23 November 2000
• WO/2000/069451: A method of identifying therapeutic compounds for a treatment of hepatic disorders, University of Newcastle, 23 November 2000
• WO/2000/066576: Isoflavone metabolites, G.J. Consultants Pty Ltd, 9 November 2000
• WO/2000/066172: Non-aqueous liquid shampoo composition, Soltec Research Pty Ltd, 9 November 2000
• WO/2000/061758: Viral variants, Melbourne Health, 19 October 2000
• WO/2000/061607: Separation of plasma components, Gradipore, 19 October 2000
• WO/2000/059520: Herbal compositions and uses for the treatment of allergic reactions, Guorang Hu , 12 October 2000
• WO/2000/058511: Screening and therapy for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3), Ludwig Institute for Cancer Research, Helsinki University and University of Pittsburgh, 5 October 2000
• WO/2000/056145: Organ arrest, protection and preservation, James Cook University, 28 September 2000
• WO/2000/052714: Heating of magnetic material by hysteresis effects, Sirtex Medical, 8 September 2000
• WO/2000/052156: Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene, Commonwealth Scientific and Industrial Research Organisation, 8 September 2000
• WO/2000/052041: Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with Porphyromonas gingivalis, University of Melbourne, CSL Ltd and Victorian Dairy Industry Authority , 8 September 2000
• WO/2000/048630: Immunogenic complexes and methods relating thereto, CSL Ltd, 24 August 2000
• WO/2000/047620: Cytokine-binding domain, Medvet Science Pty Ltd, St Vincents Institute of Medical Research, 17 August 2000
• WO/2000/046390: T helper cell epitopes, University of Melbourne, CSL Ltd, Commonwealth Scientific and Industrial Research Organisation, QIMR Berghofer Medical Research Institute, and Walter and Eliza Hall Institute of Medical Research, 10 August 2000
• WO/2000/046233: Pigment protein from coral tissue, University of Sydney, 10 August 2000
• WO/2000/041730: A composition and method for the enhancement of the efficacy of drugs, Alchemia, 20 July 2000
• WO/2000/040585: Cryptate compounds and methods for diagnosis and therapy, Australian Nuclear Science & Technology Organisation and Australian National University , 13 July 2000
• WO/2000/040262: Novel agents and methods for treatment and diagnosis of ocular disorders, Flinders University, 13 July 2000
• WO/2000/040258: Extracts of celery seed for the prevention and treatment of pain, inflammation and gastrointestinal irritation, International Celery Development Alliance Pty Ltd , 13 July 2000
• WO/2000/040244: Use of phanquinone for the treatment or prevention of memory impairment, P.N. Gerolymatos S.A., 13 July 2000
• WO/2000/039146: Miniribozymes active at low magnesium ion concentrations, Commonwealth Scientific and Industrial Research Organisation , 6 July 2000
• WO/2000/037636: SOCS box containing peptides, Walter and Eliza Hall Institute of Medical Research , 29 June 2000
• WO/2000/035478: Treatment of papillomavirus infections, University of Queensland, 22 June 2000
• WO/2000/034497: Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors, Massachusetts General Hospital, University of Zurich, University of Nijmegen and Walter and Eliza Hall Institute of Medical Research , 15 June 2000
• WO/2000/031115: Methods of identifying antigen gene sequences, Commonwealth Scientific and Industrial Research Organisation, 2 June 2000
• WO/2000/028003: Avipox vector coding an HIV antigen and a cytokine, Virax and Australian National University, 18 May 2000
• WO/2000/025801: Herbal compositions for treating gastrointestinal disorders, Chinese Medicines Scientific Consultants Pty Ltd, 11 May 2000
• WO/2000/024413: A method of treatment, Walter and Eliza Hall Institute of Medical Research, QIMR Berghofer Medical Research Institute and University of Melbourne, 4 May 2000
• WO/2000/024412: Use of VEGF-C or VEGF-D gene or protein to prevent restenosis, Ludwig Institute for Cancer Research and Helsinki University, 4 May 2000
• WO/2000/023601: Delivery system for porcine somatotropin, Commonwealth Scientific and Industrial Research Organisation, University of Western Sydney and Pig Research and Development Corporation , 27 April 2000
• WO/2000/021560: FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy, Ludwig Institute for Cancer Research and Helsinki University, 20 April 2000
• WO/2000/021538: A method of modulating ion channel functional activity, Australian National University, 20 April 2000
• WO/2000/020578: A method of modulating cell survival and reagents useful for same, Walter and Eliza Hall Institute of Medical Research, 13 April 2000
• WO/2000/020444: Novel peptides, University of Queensland, 13 April 2000
• WO/2000/020443: Novel peptides, University of Queensland , 13 April 2000
• WO/2000/015654: Cyclised conotoxin peptides, University of Queensland, 23 March 2000
• WO/2000/015254: Immunogenic compositions and uses thereof, Walter and Eliza Hall Institute of Medical Research, 23 March 2000
• WO/2000/015243: A method of treatment and agents useful for same, University of Melbourne, 23 March 2000
• WO/2000/015240: Anionic or cationic dendrimer antimicrobial or antiparasitic compositions, Starpharma, 23 March 2000
• WO/2000/015214: Fc receptor modulators and uses thereof, Ilexus Pty Ltd, 23 March 2000
• WO/2000/015193: Mousse composition, Soltec Research Pty Ltd, 23 March 2000
• WO/2000/010608: Preventives/remedies for arteriosclerosis and post-PTCA reangiostenosis, Meiji Milk Products Co., 2 March 2000
• WO/2000/009561: Monoclonal antibody inhibitor of GM-CSF, Il-3, Il-5 and other cytokines, and uses thereof, Medvet Science Pty Ltd, 24 February 2000
• WO/2000/007620: Protease inhibitors for use in the treatment of psoriasis, Biotech Australia Pty Ltd, 17 February 2000
• WO/2000/006720: A novel regulatory molecule and genetic sequences encoding same, Walter and Eliza Hall Institute of Medical Research , 10 February 2000
• WO/2000/006108: Casein formulations for the delivery of bioactive constituents, Pacific Biolink Pty Ltd, 10 February 2000
• WO/2000/004897: Bioimplant formulation, Peptech, 3 February 2000
• WO/2000/004043: Protease susceptibility II, University of Sydney, 27 January 2000
• WO/2000/003723: Polymeric compounds and methods of formulating same, Chemeq, 21 January 2000
• WO/1999/065930: Vitamin B12 derivatives and methods for their preparation, Biotech Australia Pty Ltd, 23 December 1999
• WO/1999/062955: Method of designing agonists and antagonists to EGF receptor family, Biomolecular Research Institute, Ludwig Institute for Cancer Research and Commonwealth Scientific and Industrial Research Organisation , 9 December 1999
• WO/1999/058588: Process for microgel preparation, University of Melbourne , 18 November 1999
• WO/1999/058569: Plasmin inhibitors from the Australian brown snake Pseudonaja textilis textilis, University of Queensland and National Institute of Biological Standards and Control, 18 November 1999
• WO/1999/058563: Moraxella catharralis proteins, Cortecs, 18 November 1999
• WO/1999/056697: Pharmaceutical composition, University of New South Wales, 11 November 1999
• WO/1999/054350: Novel omega conotoxin peptides, University of Queensland, 28 October 1999
• WO/1999/053923: Pharmaceutical composition, Soltec Research Pty Ltd, 28 October 1999
• WO/1999/053915: Inhibition of gram positive bacteria, University of New South Wales, 28 October 1999
• WO/1999/053050: Methods and means for obtaining modified phenotypes, Commonwealth Scientific and Industrial Research Organisation, 21 October 1999
• WO/1999/050387: Vaccination modalities, Eimeria Pty Ltd, Queensland Department of Primary Industries, and Rural Industries Research and Development Corporation, 7 October 1999
• WO/1999/049887: Use of protease inhibitors for treating skin wounds, Biotech Australia Pty Ltd, 7 October 1999
• WO/1999/049029: Control of gene expression, Benitec Biopharma and Queensland Department of Primary Industries, 30 September 1999
• WO/1999/048496: Therapy of estrogen-associated disorders, Novogen, 30 September 1999
• WO/1999/045110: V-like domain binding molecules, Diatech Pty Ltd, 10 September 1999
• WO/1999/044599: Therapeutic treatment for renal dysfunction, Eli Lilly, 10 September 1999
• WO/1999/040117: Three-dimensional structures and models of Fc receptors and uses thereof, Ilexus Pty Ltd, 12 August 1999
• WO/1999/036438: Human CMRF-35-H9 receptor which binds IgM, Sisters of Mercy in Queensland, 22 July 1999
• WO/1999/036050: Compositions and method for protecting skin from UV induced immunosuppression and skin damage, Novogen, 22 July 1999
• WO/1999/033485: Expression vectors and cell lines expressing Vascular Endothelial Growth Factor D, and method of treating melanomas, Ludwig Institute for Cancer Research, 8 July 1999
• WO/1999/032597: Stable emulsions, Dow Corning, 1 July 1999
• WO/1999/031132: Novel surface protein of Neisseria meningitidis, University of Queensland, 24 June 1999
• WO/1999/029870: Porphorymonas gingivalis polypeptides and nucleotides, CSL Ltd, 17 June 1999
• WO/1999/027959: Saponin adjuvant composition, Commonwealth Scientific and Industrial Research Organisation, 10 June 1999
• WO/1999/027950: Compositions of Leukaemia Inhibitory Factor, Amrad, 10 June 1999
• WO/1999/026971: Antimicrobial peptides, Victorian Dairy Industry Authority, 3 June 1999
• WO/1999/024470: Mammalian milk growth factor, Gropep, 20 May 1999
• WO/1999/023217: A novel gene and uses therefor, International Diabetes Institute and Deakin University, 14 May 1999
• WO/1999/021975: Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor, Australian National University, 6 May 1999
• WO/1999/019351: Novel NPY family member, Garvan Institute of Medical Research , 22 April 1999
• WO/1999/018992: Oromucosal cytokine compositions and uses thereof, Pharma Pacific Pty Ltd, 22 April 1999
• WO/1999/018974: Use of sulfated oligosaccharides in lowering blood triglyceride levels, Australian National University, 22 April 1999
• WO/1999/016455: Mannose receptor bearing cell line and antigen composition, Austin Research Institute, 8 April 1999
• WO/1999/016417: Buccal, polar and non-polar spray or capsule, Suda Pharmaceuticals, 8 April 1999
• WO/1999/016406: Therapeutic method, University of Auckland, 8 April 1999
• WO/1999/014321: Novel therapeutic molecules, Walter and Eliza Hall Institute of Medical Research, 25 March 1999
• WO/1999/012969: Treatment of obesity, Metabolic Pharmaceuticals, 18 March 1999
• WO/1999/012533: A method of modulating cellular activity, Medvet Science Pty Ltd, 18 March 1999
• WO/1999/011703: Cross-linked particles, Biotech Australia Pty Ltd, 11 March 1999
• WO/1999/011273: Use of sulfated oligosaccharides as inhibitors of cardiovascular disease, Australian National University , 11 March 1999
• WO/1999/009981: Use of phanquinone for the treatment of Alzheimer's disease, P.N. Gerolymatos S.A., 4 March 1999
• WO/1999/008994: Anti-cancer compounds, Peplin Biotech, 25 February 1999
• WO/1999/008706: Recombinant porcine adenovirus vector, Commonwealth Scientific and Industrial Research Organisation and Pig Research Development Corporation, 25 February 1999
• WO/1999/004826: Method for detection of fibrin clots, Australian National University , 4 February 1999
• WO/1999/003886: Tropoelastin derivatives, University of Sydney, 28 January 1999
• WO/1999/003328: Toxin genes from the bacteria Xenorhabdus nematophilus and Photorhabdus luminescens, Commonwealth Scientific and Industrial Research Organisation , 28 January 1999
• WO/1999/002694: Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue, University of Queensland, 21 January 1999
• WO/1999/002550: CTL epitopes from EBV, QIMR Berghofer Medical Research Institute, Commonwealth Scientific and Industrial Research Organisation, University of Melbourne, Walter and Eliza Hall Institute of Medical Research and CSL Ltd, 21 January 1999
• WO/1999/001149: Health supplement, Sigma Pharmaceuticals, 14 January 1999
• WO/1999/000406: Cyclic agonists and antagonists of c5a receptors and G Protein-Coupled Receptors, University of Queensland , 7 January 1999
• WO/1999/000136: Control of acidic gut syndrome, University of New England , 7 January 1999
• WO/1998/058939: Neurologically-active compounds, Polychip Pharmaceuticals Ptd Ltd and University of Sydney , 30 December 1998
• WO/1998/056420: Ganglioside immunostimulating complexes and uses thereof, CSL Ltd, 17 December 1998
• WO/1998/056387: Method of treatment of liver tumours and pharmaceutical compositions for use therein, University of New South Wales, 17 December 1998
• WO/1998/053036: Alkylpolyglucosides containing disinfectant compositions active against Pseudomonas microorganism, Novapharm Research, 26 November 1998
• WO/1998/052525: Sunscreen composition, Soltec Research Pty Ltd, 26 November 1998
• WO/1998/051790: A novel nucleic acid molecule, Amrad, 19 November 1998
• WO/1998/049192: Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis, University of Melbourne, Victorian Dairy Industry Authority and CSL Ltd, 5 November 1998
• WO/1998/044129: Enhancement of immune response using targeting molecules, Queensland Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation, University of Melbourne, Walter and Eliza Hall Institute of Medical Research and CSL Ltd, 8 October 1998
• WO/1998/042331: Mediation of circadian rhythms, Luminis Pty Ltd, 1 October 1998
• WO/1998/042326: Fungal sulphur source and method of using the same, Commonwealth Scientific and Industrial Research Organisation and Australian Wool Research and Promotion Organisation , 1 October 1998
• WO/1998/041218: An aqueous metal bicarbonate solution and method of use, Macquarie Veterinary Supplies Pty Ltd, 24 September 1998
• WO/1998/040406: Calcium phosphopeptide complexes, University of Melbourne and Victorian Dairy Industry Authority, 17 September 1998
• WO/1998/040081: Sulfated oligosaccharides having anticoagulant/antithrombotic activity, Australian National University, 17 September 1998
• WO/1998/039021: Treatment and diagnosis of infertility using TGFβ or activin, Luminis Pty Ltd, 11 September 1998
• WO/1998/038291: Component of bromelain, Cortecs, 3 September 1998
• WO/1998/036772: Chelating immunostimulating complexes, CSL Ltd, 27 August 1998
• WO/1998/036054: Novel molecules, Amrad, 20 August 1998
• WO/1998/033917: Vascular Endothelial Growth Factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof, Ludwig Institute for Cancer Research and University of Helsinki, 6 August 1998
• WO/1998/032769: Antigen, Auspharm International Ltd, 30 July 1998
• WO/1998/031819: Expression in yeast of antigenically active, recombinant hybrid glutamic acid decarboxylase, Montech Medical Developments Pty Ltd and Rondole Pty Ltd , 23 July 1998
• WO/1998/031739: A process for preparing polymeric microgels, University of Melbourne, 23 July 1998
• WO/1998/030124: Insect repellent substrate for headwear, Lice Busters International Pty Ltd, 16 July 1998
• WO/1998/027996: A method of treatment and prophylaxis, Amrad, 2 July 1998
• WO/1998/027927: Apparatus and method for coating a material, Scientec Research Pty Ltd, 2 July 1998
• WO/1998/027805: Antimicrobial proteins, Cooperative Research Centre for Tropical Plant Pathology, 2 July 1998
• WO/1998/026784: A method for preventing or controlling cataract, University of Sydney, 25 June 1998

---

Copyright © 2018 NDF Research